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Abstract 
 
A 21-year-old Chinese gentleman with no known medical illness, presented with a history of right painless blurring 
of vision with central scotoma of two weeks duration. He also had  a history of multiple episodes of seizures prior to 
presentation. Visual acuity was 1/60 with unremarkable anterior segment findings and no relative afferent pupillary 
defect. Fundus examination of the right eye revealed dilated and tortuous retinal veins with multiple retinal capillary 
hemangiomas and sub retinal hard exudates at the macula with edema. A diagnosis of Von Hippel Lindau disease 
was made when a posterior fossa mass suggestive of hemangioblastoma with obstructive hydrocephalus was seen on 
computed tomography of the brain. Craniotomy with nodule excision  was performed. The retinal capillary 
hemangiomas were treated with the combination of laser photocoagulation and intravitreal Ranibizumab injections. 
Visual acuity subsequently improved to 6/36. 
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Introduction 
 
Von Hippel Lindau (VHL) disease is a highly 
penetrant, heritable, autosomal dominant multisystem 
cancer syndrome. The germ line mutation of the Von 
Hippel Lindau tumour suppressor gene is located on 
the short arm of chromosome 3. Affected individuals 
may present with central nervous system (CNS) and 
retinal haemangioblastomas, renal clear cell 
carcinoma, phaeochromocytoma and also 
endolymphatic sac tumours (1). We report a case with 
retinal haemangioblastoma with history of presumed 
seizure episodes, alarming the possibility of VHL 
disease.  
 
 
Case Report 
 
A 21-year-old Chinese gentleman complained of 
painless blurring of vision in the right eye associated 
with central scotoma for two weeks prior to 
presentation. He reported history of multiple episodes 
of seizures. He never sought any treatment for these 
presumed-seizure episodes, and thus was never 
properly investigated. 
  
At presentation, visual acuity in the right eye was 1/60 
and 6/6 in the left eye. Anterior segments findings in 
the right eye were normal with no relative afferent 
pupillary defect. Retinal capillary haemangiomas (RCHs) 
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Figure 1: (a) Fundus photographs showing dilated, tortuous retinal veins (black arrow), large subretinal hard exudate at macula 
with edema (white arrow), (b) RHC on presentation (black arrow) and (c) post- laser and intravitreal Ranibizumab injections. 
 
 
 
 
Figure 2: (a) OCT macula thickness: pre injection, (b) post injection 
 
 
Figure 3: (a) Preoperative cystic posterior fossa tumor and (b) post-op encaphalomalacia with no residual tumor 
 
measuring about 1.5–2 mm associated with dilated and 
tortuous retinal veins, large multiple subretinal hard 
exudates at macula with edema were seen in the right 
eye (Fig. 1). Central macular thickness (CMT) on 
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Optical Coherence Tomography (OCT) measured 
602μm (Fig. 2a).  Left eye was normal. Fundus 
fluorescein angiogram revealed numerous areas of 
hyper fluorescence with dilated and tortuous feeder 
vessels, late leakage and masking over the macula.  
  
Computed tomography (CT) revealed a posterior fossa 
cystic mass measuring 4.0 x 5.5 x 4.9 cm with an 
enhancing mural nodule and retinal lesions suggestive 
of hemangioblastoma with associated obstructive 
hydrocephalus (Fig. 3a). A diagnosis of Von Hippel 
Lindau (VHL) disease was established. Systemic 
review and ultra-sonogram examination of abdomen 
were normal. 
  
The RCHs was treated with argon laser 
photocoagulation. A total of 8 intravitreal 
Ranibizumab injections were given monthly over a 
period of 8 months. The RCHs responded to treatment 
(Fig. 1c). Vision became 6/36 and central scotoma had 
improved with reduction of CMT to 467 μm (Fig. 2b). 
  
Craniotomy for cyst evacuation and nodule excision 
was performed. Histopathological result had 
concluded the nodule to be hemangioblastoma World 
Health Organization (WHO) Grade 1 with no evidence 
of neoplastic cells. Postoperative MRI showed 
evidence of residual disease with cystic spaces in the 
posterior fossa measuring 2.1 x 3.0 x 1.5 cm and 
intramedullary cervical spinal cord 
haemangioblastoma measuring 1.5 x 2.5 cm. Repeat 
craniotomy with complete tumour evacuation was 
performed (Fig. 3b).  5 cycles of radiotherapy was 
given for the spinal cord with regression of tumour to 
a size of 0.5 x 1.5 cm. 
  
Repeat MRI 6 months later showed evidence of new 
cerebellar hemangioblastoma. However, he is being 
managed conservatively as it has remained unchanged 
on repeated scans. He has been scheduled for a 6-
monthly MRI of cerebellum and spine and annual 
catecholamine and abdominal ultrasonography for 
monitoring. 
 
Discussion 
 
The affected gene in VHL produces a tumor 
suppressor product known as pVHL. A germ line 
mutation at chromosome 3p25 results in cells lacking 
pVHL. These abnormal cells are associated with the 
overproduction of angiogenic products, such as 
erythropoietin, vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF). 
These cells also do not degrade hypoxia-inducible 
factors (HIF) in the presence of oxygen. VHL 
associated tumors have high HIF gene levels in all 
tumor cells, making them highly vascular (2).  
  
RCHs have been identified as the earliest and the most 
frequent manifestation of this disease, as high as 60% 
with the mean age of 25 years at presentation. RCHs 
manifests as a solitary tumour, appearing as round and 
circumscribed retinal lesion with an orange-red hue at 
any part of the retina. It can be exophytic, endophytic 
or sessile in nature with presence of subretinal and 
intraretinal exudation. Less than 3% of cases present 
with vitreous or retinal haemorrhage (3). 
Juxtapapillary type of RCHs is commonly seen along 
the the optic disc at the temporal quadrant in 11–15% 
of VHL disease. Anterior segment rubeosis may be 
seen at a later stage of the disease. Neuro-ophthalmic 
manifestations such as optic nerve compression and 
chiasmal syndrome are rare (3). 
  
Untreated RCHs can lead to sight threatening 
complications such as retinal exudation with macula 
edema, and traction with consequent exudative or 
tractional retinal detachments, as high as 16% and 9% 
respectively (3). Initial close observation of RCH is 
recommended in specified cases of small nasally 
located lesions (up to 500 μm) without exudation, 
subretinal fluid or juxtapapillary type of RHCs.  
 
Argon laser photocoagulation is the commonest mode 
of treatment which can be delivered to the feeder 
vessels, to the tumour itself or both. Clinical responses 
are seen in 91–100% of cases (4). Laser 
photocoagulation is the treatment of choice in 
posterior RCH which measures 1.5 mm or smaller, or 
even up to 4.5 mm. RCHs in this case which is 
considered in this group showed good response to 
laser photocoagulation.  
  
Cryotherapy is preferable to photocoagulation when 
the RCHs are anterior and more than 3.0 mm with a 
significant amount of subretinal fluid. Advanced cases 
may require pars plana vitrectomy. Juxtapapillary 
RCH generally carries a poorer visual prognosis (4). 
  
Photodynamic therapy (PDT) with verteporfin has 
been advocated with sustained visual outcome for 22 
months by Rarey and Friberg (5). RCH greater than 
4mm may benefit from radiotherapy as they often 
respond poorly to cryotherapy and laser 
photocoagulation. External beam, proton beam or 
plaque radiotherapy has been advocated (6). 
  
Anti-vascular endothelial growth factor (VEGF) such 
as Ranibizumab and Bevazicumab play a critical role 
in controlling the disease directly by halting VEGF 
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expression in the rapidly growing tumors. Intravitreal 
Ranibizumab monotherapy is demonstrated to achieve 
the best clinical effect when the lesions are smallest 
and minimally exudative as they are associated with a 
high cell turnover and increased sensitivity to 
antiangiogenic inhibitory effects (7). It can be 
advocated as many times until complete resolution of 
exudative macula edema and regression of RCHs, 
however caution has to be undertaken in cases of pre-
existing tractional component. 
  
CNS haemangioblastomas (WHO Grade I) represent 
0.9–2.1% of all intracranial neoplasms and are the 
second commonest presentation of VHL. They are 
noted to be identical microscopically as well as 
histologically to the sporadic type, regardless of their 
location. VHL associated tumors tend to be multiple, 
whereas the sporadic types are usually solitary. They 
stand a risk of having new RCH one per 2.1 years (8).  
  
Commonest VHL associated CNS haemangioblastoma 
is the craniospinal type, involving cerebellum in 
majority of cases (44–72%), as observed in this case. 
Less frequent sites are in the spinal cord (13–50%), 
followed by brainstem (10–20%) and supratentorial 
region (3–6%). These tumors typically appear brightly 
enhancing on MRI with a clear demarcation from the 
surrounding tissue. Vascular flow voids in the 
presence of major feeder vessels are often identified 
(8). 
  
Surgical intervention is always the treatment of choice 
for CNS tumors, taking into consideration the post-
operative morbidity and residual CNS deficits and the 
risk of repeated surgeries.  Generally subsequent 
surgeries may be considered if the tumor size post 
initial resection is of larger than 3cm and posterior 
fossa in location.  
 
Subtotally resected tumors respond well to 
radiotherapy (RT) in 60% -90% of cases showing local 
regression. Resected base with a uniformly 
symmetrical margin of 1cm should be included as the 
clinical target volume (CTV), with a prescription dose 
within the range 50–60 Gy having per fraction value of 
1.8 or 2.0 Gy (9). High doses in cases of smaller tumor 
volume is associated with a better response rate 
radiation however still carries a risk of peritumoral 
edema and radiation necrosis. 
 
Unresectable spinal cord hemangioblastoma has been 
shown to produce significant tumor regression when 
treated with intravenous bevacizumab therapy (10). 
 
 
 
Conclusion 
 
RCHs are commonly the earliest presentation of VHL, 
as in this scenario. Therefore, when RCHs are 
confirmed in a patient, further detailed history and a 
thorough systemic review is vital, in making a precise 
diagnosis with a multidisciplinary approach. This is 
important as VHL disease can lead to sight and life 
threatening complications if left undiagnosed and 
untreated at the right time. 
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